PressureStim a Leonhardt Ventures Co. Announces Licensing of Patent Portfolio for Bioelectric Blood Pressure Management from Neuro Code Tech Holdings LLC Expanding Its Intellectual Property Estate.

Press Release – Santa Monica, California and Albuquerque, New Mexico, September 22nd, 2017 – PressureStim, an emerging leader in bioelectric blood pressure management announced today that the Company has entered into an option agreement that leads to an exclusive license with Neuro Code Tech Holdings LLC for key pioneering patents in the field of bioelectric management of blood pressure. PressureStim is a unit of Leonhardt Ventures which is incubating in Leonhardt’s Launchpads by Cal-X Star Business Accelerator, Inc. and Leonhardt’s Launchpads Utah, Inc.

Implantable method to regulate blood pressure by means of coded nerve signals

Patent number: 6957106
Abstract: A method and device for modulating blood pressure. The method comprises selecting waveforms from a storage area that are representative of body organ function. The selected waveforms are then transmitted to a treatment member, which is in direct contact with the body, and which then broadcasts the waveforms to a blood pressure regulatory points within the body to modulate blood pressure. A control module is provided for transmission to the treatment member. The control module contains the waveforms which are selected and transmitted to the treatment member, and computer storage can be provided for greater storage capacity and manipulation of the waveforms.

Type: Grant
Filed: February 18, 2004
Date of Patent: October 18, 2005
Inventors: Eleanor Schuler, Claude K. Lee

Implantable method to regulate blood pressure by means of coded nerve signals

Publication number: 20040236238

Abstract: A method and device for modulating blood pressure. The method comprises selecting waveforms from a storage area that are representative of body organ function. The selected waveforms are then transmitted to a treatment member, which is in direct contact with the body, and which then broadcasts the waveforms to a blood pressure regulatory points within the body to modulate blood pressure. A control module is provided for transmission to the treatment member. The control module contains the waveforms which are selected and transmitted to the treatment member, and computer storage can be provided for greater storage capacity and manipulation of the waveforms.

Type: Application
Filed: February 18, 2004
Publication date: November 25, 2004
Inventors: Eleanor Schuler, Claude K. Lee

“By licensing these patents that relate to PressureStim bioelectric blood pressure management technology, PressureStim continues to build upon its emerging technology and defend its platform technology platform as we simultaneously move forward step by step to meet all requirements with regulatory authorities to be able initiate studies that will investigate the PressureStim device in both OUS and U.S. clinical trials.” stated Howard J. Leonhardt, Founder, Executive Chairman and CEO.

“Hypertension is an enormous healthcare problem, with 30% of American adults having hypertension. About half of hypertensive adults in the US have their blood pressure under control while the other half remain at an unhealthy level. Hypertension is a major and independent contributor to cardiovascular events, increasing the risk of CHD, heart failure, and stroke from two- to four-fold. Isolated systolic hypertension is a strong risk factor for cardiovascular mortality and is the most prevalent precursor to heart failure in the elderly population. Treatment of isolated systolic hypertension has been shown to decrease the incidence of stroke, MI, heart failure, and kidney failure in a number of clinical trials in older patients. The high rate of un-manageable hypertension despite all the drugs on the market targeting this condition strongly suggests that a better alternative is needed. We are prepared to enter careful pre-clinical and then clinical studies over the next many years to determine whether PressureStim is indeed a worthy alternative. Independent studies in China and other locations by earlier investigators of bioelectric stimulation have demonstrated improvement in blood pressure management – see https://leonhardtventures.com/pressurestim/ for additional information. We believe, based on our internal lab studies, we have refined the preciseness of bioelectric signaling beyond those earlier studies to have more accurate control of expressions of particular beneficial proteins on demand.” stated Dr. Leslie Miller, Chief Medical Officer, PressureStim

“This additional intellectual property from Neuro Code Tech Holdings LLC and Science Medicus, Inc. expands the breadth of the Company’s already comprehensive bioelectric organ regeneration and recovery patent portfolio, which portfolio includes inventions relating to critical aspects of bioelectric stimulation controlled stem cell homing, proliferation and differentiation as well as more than 16 different regeneration promoting proteins, cancer tumor treatment and accelerated tooth movement and stabilization.” states Asli Gozoren Director of Investor Relations.

About PressureStim LTP

PressureStim LTP is a Licensable Technology Platform startup incubating within the Leonhardt’s Launchpads innovation and startup accelerators in California and Utah. It is focused on bioelectric treatment of hypertension via a patented and patent pending bioelectric stimulator technology platform. PressureStim LTP is majority owned by Leonhardt Ventures (Leonhardt Vineyards LLC DBA Leonhardt Ventures). See https://leonhardtventures.com/pressurestim/

About Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc.

Leonhardt’s Launchpads is an innovation and startup launch accelerator focused on regenerative medtech innovations which began operations in Northern California in 2008 and opened up in Santa Monica, California in 2012 and in Salt Lake City, Utah in 2015. Cal-X Stars Business Accelerator, Inc. was incorporated in California in 2013 and in Leonhardt’s Launchpads Utah, Inc was incorporated in Utah in 2016. The accelerator/incubators in three locations currently have 26 regenerative medtech and 4 regenerative economy startups and licensable technology platforms (LTP’s) in their 2017 portfolio. Nearly all of the organ regeneration and recovery startups are based on the same core patented and patent pending technology of a bioelectric stimulator often combined with a micro infusion pump and a multi component stem cell + growth factor based organ regeneration composition. The business model of our innovation and startup accelerators is to advance each organ specific startup through first-in-man studies and then seek a strategic buyer/parter preferably with a 3% royalty forward on net sales. The maximum amount of time a startup normally stays within the innovation & startup accelerators is 5 years. The innovation accelerators have access to research labs in Santa Monica, Salt Lake City and Petaluma California. In Utah we are a member of USTAR’s BioInnovation Gateway laboratory with access to a number of other research facilities. See www.calxstars.com + www.leonhardtventures.com for more information.

About Leonhardt Ventures

Leonhardt Ventures was originally founded in 1982 as H.J. Leonhardt & Co. and was formed into a California LLC (Leonhardt Vineyards LLC DBA Leonhardt Ventures) in 2005. It is 100% owned by Howard J. Leonhardt and is the origin firm for his innovations, patents, concepts and startups. Howard J. Leonhardt is an inventor with over 20 issued patents and dozens of new patent claims pending. In the 1980’s he patented and developed a market leading predictably compliant cardiovascular balloon catheter – PolyCath, in the 1990’s the first percutaneous heart valve – ValveStent, the first intravascular lung catheter – PENSIL, one of the first stem cell delivery catheters – ProCell, a electromagentic radiation delivery catheter – RadiCath and the first commercially successful stent graft – TALENT and one of the first biological pacemakers – BioPace. In 1995 he led a team the completed the world’s first percutaneous repair of an aortic aneurysm in Australia with Dr. Kenneth Thomson. In 1998 he lead a team that published the first paper in the New England Journal of Medicine with Dr. Christof Niebaber of endovascular repair of aortic Type B dissections, in 1999 he helped lead a team that published the first paper on bioelectric regeneration of blood flow in ischemic legs in CIRCULATION and resulting U.S. issued patent claims working with Dr. Shinichi Kanno, In 2000 he began filing the first series of patents on bioelectric driven organ regeneration combined when necessary with a micro infusion pump and repeat deliveries of a mixed stem cell + growth factor organ regeneration composition. In 2001 he helped lead the historic landmark world’s first non-surgical stem cell repair of a human heart in The Netherlands with Prof. Patrick Serruys. Over 400,000 patients have been treated with Leonhardt inventions to date in over 40 countries.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy, the Company’s ability to develop and grow its business, the successful development of bioelectric or cellular therapies with respect to the Company’s research and development and pre-clinical + clinical evaluation efforts in connection with the Company’s bioelectric organ regeneration and recovery programs (including whether or not PressureStim will successfully be developed to treat metastatic melanoma or any other cancer indications), Ischemic Repair Program, Immune Modulation Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the performance and planned expansion of the Company’s contract development and manufacturing business. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report, Private Placement Memorandums and newsletter updates and in the Company’s other periodic filings with the SEC and state agencies. The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside its control. The innovation accelerator business model based on simultaneously developing 30+ products and startups at once with a small staff and a small budget leaves the company at greater risks than other stand alone startups. Information on all associated web sites may not always be up to date and accurate. If you have any specific questions please write directly to our CEO at howard@leonhardtventures.com or Asli Gozoren our Director of Investor Relations at asli@leonhardtventures.com

Link to Leonhardt Ventures 2017 Annual Report > http://2ho06i23weps2hx3g346udzo-wpengine.netdna-ssl.com/wp-content/uploads/2017/08/cal-x_stars_annual-report_2017_v12_web.pdf